---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-016275"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:08:45.815685+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Zevra Therapeutics shareholders reject amendments to 2014 Equity Incentive Plan at annual meeting

## Summary
- Three Class III directors elected: Thomas D. Anderson, Neil F. McFarlane, Alvin Shih, M.D.
- Shareholders ratified Ernst & Young LLP as independent auditor for FY2024.
- Advisory say-on-pay vote approved (11.2M for, 9.9M against).
- Proposal to amend 2014 Equity Incentive Plan failed: 4.1M for, 17.0M against, 9.9M broker non-votes.
- Approximately 74.5% of shares represented at the meeting.

## SEC filing metadata
- accession: 0001437749-24-016275
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/zvra20240513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-016275
- JSON: https://secwatch.observer/filing/0001437749-24-016275.json
- Plain text: https://secwatch.observer/filing/0001437749-24-016275.txt

## Key facts
- Shareholder Votes
  ZEVRA THERAPEUTICS, INC. shareholders approved Election of Alvin Shih, M.D. as a Class III director at the 2024-05-13 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2024-05-13
  source text: Anderson 15,266,761 6,062,268 9,865,186 Neil F. McFarlane 12,413,828 8,915,201 9,865,186 Alvin Shih, M.D. 16,592,152 4,736,877 9,865,186 For Against Abstentions Broker Non-Votes 2.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm
- Shareholder Votes
  ZEVRA THERAPEUTICS, INC. shareholders approved Election of Neil F. McFarlane as a Class III director at the 2024-05-13 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2024-05-13
  source text: Anderson 15,266,761 6,062,268 9,865,186 Neil F. McFarlane 12,413,828 8,915,201 9,865,186 Alvin Shih, M.D. 16,592,152 4,736,877 9,865,186 For Against Abstentions Broker Non-Votes 2.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm
- Shareholder Votes
  ZEVRA THERAPEUTICS, INC. shareholders approved Election of Thomas D. Anderson as a Class III director at the 2024-05-13 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2024-05-13
  source text: 1. Election of Directors For Withheld Broker Non-Votes Thomas D. Anderson 15,266,761 6,062,268 9,865,186
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm
- Shareholder Votes
  ZEVRA THERAPEUTICS, INC. shareholders approved Advisory approval of compensation of named executive officers at the 2024-05-13 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2024-05-13
  source text: 3. Approval, on an advisory and non-binding basis, of the compensation of the Company's named executive officers. 11,167,215 9,888,153 273,661 9,865,186
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm
- Shareholder Votes
  ZEVRA THERAPEUTICS, INC. shareholders rejected Approval of amendments to the Company's Amended and Restated 2014 Equity Incentive Plan at the 2024-05-13 meeting.
  - Proposal: equity plan
  - Outcome: failed
  - Meeting: 2024-05-13
  source text: 4. Approval of amendments to the Company's Amended and Restated 2014 Equity Incentive Plan 4,143,728 16,964,060 221,241 9,865,186
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm
- Shareholder Votes
  ZEVRA THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-13 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2024-05-13
  source text: 2. Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company ’ s fiscal year ending December 31, 2024. 22,543,306 7,352,086 1,298,823 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.